CHICAGO--(BUSINESS WIRE)--Feb. 19, 2004--Targeted Molecular Diagnostics, LLC. (TMD), an advanced cancer diagnostic laboratory providing top professional services to Bio-Pharmaceutical companies and physicians, has established a Scientific Advisory Board of well-recognized physicians and scientists. Initial appointments are named below, and TMD is in the process of recruiting a select number of additional internationally known oncologists.
Dr. Yosef Yarden, a Professor of Molecular Biology at Weizmann Institute of Science, has been named Chairman of the Board. Dr. Yarden is a world known leader, and a pioneer in the field of the mechanism of oncogenes and their role in the development and the biological behavior of cancer.
Dr. James Abbruzzese, Chairman and Professor of Medicine at the Department of GI Oncology at MD Anderson Cancer Center, is a leader in the field of pancreatic cancer oncology and therapy.
Dr. Carlos Arteaga, a Professor of Medicine Cancer Biology at Vanderbilt School of Medicine, is a leading researcher in cancer biology.
Dr. Gabriel Hortobagyi, Professor and Chairman of the Department of Breast Medical Oncology at MD Anderson Cancer Center, is a world renowned oncologist in the field of breast cancer oncology and therapy. He is responsible for the development of numerous therapeutics for treatment of breast cancer.
Dr. Rony Seger, an Associate Professor at the Department of Biological Regulation at Weizmann Institute of Science, is a leader in the field of cell signaling.
Dr. David Sidransky, a Director of the Head and Neck Cancer Research Division of Johns Hopkins University School of Medicine, is a leader and pioneer in cancer biology and cancer prevention. He leads research and a clinical group for head and neck cancer.
"We are proud to welcome such accomplished and respected scientists and oncologists to our board," says Sarah Bacus, PhD, founder, president and Chief Executive Officer of TMD. "By establishing the Scientific Advisory Board, we are positioning our company at the forefront of cancer research in diagnostics and therapeutics."
Sarah Bacus, PhD, former QDL Chief Scientific Officer is a renowned scientist who holds numerous patents and is a leader in developing targeted diagnostics in the field of cancer therapy. Along with her team, she has been active in the field of cancer diagnostics for over twenty years. "Bio-Pharmaceutical companies are devoted to the development of novel therapeutic tools," states Dr. Bacus. "Our state-of-the-art laboratory and our clinical research staff will enhance and accelerate their efforts."
ABOUT TARGETED MOLECULAR DIAGNOSTICS, LLC:
TMD is a privately held, oncology focused, specialty reference laboratory. TMD provides Bio-Pharmaceutical companies with biomarker assays for molecular targeted drugs, from pre-clinical to First Time in Humans (FTIH), and through Phase II and Phase III clinical trials. In addition, TMD helps define subpopulations of tumors that will respond to targeted cancer therapies by understanding the drug mechanism of action. As a result, it is possible to accelerate the time to regulatory approval. TMD applies cutting-edge in vitro assays to enable pre-treatment patient assessment, and identifies markers that predict response and adverse events. Based on this information, TMD is developing predictive tests for managing cancer patients, by defining molecular characteristics of their tumors to guide targeted therapy. TMD is establishing strategic alliances with leading pharmaceutical and reagent companies to develop regulatory approved tests for many targeted therapies which will be the subject of future announcements.
Contacts
Targeted Molecular Diagnostics, LLC. Sara Simchoni, 630-789 1233 ssimchoni@tmdlab.com
